Nuvation Bio (NYSE:NUVB) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 16.67 percent increase over losses of $(0.12) per share from the same period last year.
Wells Fargo Maintains Overweight on Nike, Raises Price Target to $146
Wells Fargo analyst Kate Fitzsimons maintains Nike (NYSE:NKE) with a Overweight and raises the price target from $135 to $146.
